Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond PVR: dynamic physiologic assessment enhances prognostic evaluation in pulmonary hypertension associated with chronic obstructive pulmonary disease.

BMJ open respiratory research·2026

Same author

Stiff Left Atrial Syndrome: Hemodynamic Insights and a Noninvasive Diagnostic Approach.

Annals of the American Thoracic Society·2026

Same author

Right Ventricular End-Ejection Pressure Predicts Mortality in Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Comprehensive Physiology·2026

Same author

Comparative Pulmonary Artery Pressure Response between Large-Bore Thrombectomy and Catheter-Directed Thrombolysis in Patients with Intermediate-High- and High-Risk Pulmonary Embolism.

Journal of vascular and interventional radiology : JVIR·2026

Same author

Reply to Sbarra et al.

American journal of physiology. Heart and circulatory physiology·2026

Same author

Pre-capillary Pulmonary Hypertension in a Patient with Interlobular Septal Thickening and Prominent Mediastinal Lymphadenopathy.

Annals of the American Thoracic Society·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Inderjit Singh¹, Aurora Pujol

¹Department of Pediatrics, Darby Children Research Institute, Medical University of South Carolina, Charleston, SC, USA.

Brain Pathology (Zurich, Switzerland)

|July 15, 2010

Summary

X-adrenoleukodystrophy (X-ALD) involves ABCD1 gene inactivation, leading to varied phenotypes like cerebral ALD (cALD) or adrenomyeloneuropathy (AMN). Understanding the molecular mechanisms behind cALD

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Targeted Knockdown of Genes in the Choroid Plexus

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Related Experiment Videos

Last Updated: Jun 11, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Targeted Knockdown of Genes in the Choroid Plexus

Targeted Knockdown of Genes in the Choroid Plexus

Published on: June 16, 2023

Area of Science:

Biochemistry
Genetics
Neurology

Background:

X-adrenoleukodystrophy (X-ALD) is a genetic disorder caused by ABCD1 gene mutations.
It leads to the accumulation of very long chain fatty acids (VLCFA), a hallmark of the disease.
X-ALD presents with diverse clinical phenotypes, including cerebral ALD (cALD) and adrenomyeloneuropathy (AMN).

Purpose of the Study:

To explore the underlying molecular mechanisms of X-ALD phenotypes.
To investigate the ABCD1-mediated pathways contributing to disease diversity.
To propose a framework for understanding cerebral ALD (cALD) neuropathology.

Main Methods:

Review of existing studies on X-ALD pathogenesis.
Analysis of the role of ABCD1 gene function in very long chain fatty acid (VLCFA) metabolism.
Examination of molecular mechanisms underlying different X-ALD phenotypes.

Main Results:

ABCD1 gene inactivation impairs very long chain fatty acid (VLCFA) beta-oxidation.
Excessive VLCFA accumulation is a key biochemical feature of X-ALD.
A "three-hit hypothesis" is proposed for the neuropathology of cerebral ALD (cALD).

Conclusions:

The precise mechanisms dictating X-ALD phenotypes remain unclear.
Understanding the molecular basis of cALD's three phases is crucial.
This knowledge may lead to targeted pharmacological treatments for X-ALD.